

Table A.7a: Longer-Run Treatment Effects (ITT)

	(1)	(2)	(3)	(4)	(5)
Outcome Variable	Horizon (months)	Mean	No Controls	Strata FEs	Post-Lasso
<b>A. Medical Spending [admin]</b>					
Total spending (dollars/month) [admin]	30	650.5	-74.7 (58.5) [0.611] <i>N</i> =3,307	N/A N/A N/A	N/A N/A N/A
Drug spending [admin]	30	148.8	-25.2 (27.7) [0.841] <i>N</i> =3,307	N/A N/A N/A	N/A N/A N/A
Office spending [admin]	30	74.2	-6.6 (8.6) [0.841] <i>N</i> =3,307	N/A N/A N/A	N/A N/A N/A
Hospital spending [admin]	30	353.5	-31.7 (35.6) [0.841] <i>N</i> =3,307	N/A N/A N/A	N/A N/A N/A
Nonzero medical spending [admin]	30	0.950	0.005 (0.008) [0.841] <i>N</i> =3,307	N/A N/A N/A	N/A N/A N/A

Notes: This table replicates Appendix Table A.7a from Jones, Molitor, and Reif (QJE 2019) using public-use data. The Westfall-Young *p*-values, reported in brackets, do not exactly replicate the values from the original paper due to censoring in the public-use data. N/A indicates a censored value.